Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion

  • Jing Chen1
  • Fei Wang2
  • Shanshan Wang3
  • Xuyang Song4
  • Chia-Chi Lin5
  • Xiaodong Tang6
  • Xuyang Lu7
  • Yutao Liu8
  • Herbert H Loong9
  • Liu Jiayong10
  • Niu Xiaohui11
  • Chung Cheung Thomas Yau12
1 more authors
  • Archie Tse13
13 affiliations
  1. 1Huazhong University of Science and Technology, Wuhan, China
  2. 2Department of Anesthesiology, The 960th Hospital of People’s Liberation Army of China (PLA), Jinan, Shandong, China
  3. 3Department of Pharmacology, State Key Laboratory of Experimental Hematology, Tianjin Key Laboratory of Inflammatory Biology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China
  4. 47Adlai Nortye USA Inc., North Brunswick, NJ, USA
  5. 5National Taiwan University Hospital, Taipei, Taiwan
  6. 61Renmin Hospital, Beijing, China
  7. 76Adlai Nortye Biopharma Co., Ltd., Hangzhou, China
  8. 8Chinese Academy of Medicine, Shanghai, China
  9. 9The Chinese University of Hong Kong, Hong Kong SAR, China
  10. 10Beijing Cancer Hospital, Beijing, China
  11. 11Beijing Jishuitan Hospital, Beijing, China
  12. 12The University of Hong Kong, Hong Kong SAR, China
  13. 13Adlai Nortye Biopharma Co., Ltd., Hangzhou, China
Open at sourceDOICite

Related

  1. Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study
    Masaki Ishida, Tadaaki Yamada, Riko Kamada +19
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyPMCCrossrefEurope PMC
  2. Resistance-Mutant Rescue Establishes On-Target CHI3L1 Inhibition by CHI-DEL, a Brain-Penetrant Small Molecule with In Vivo Efficacy in Glioblastoma
    S. Upadhyay, L. Zhang, M. Teplova +2
    bioRxivPreprintAll rights reservedFull textNeurosciencebioRxiv
  3. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
    Elie Rassy, Cécile Dalban, Emeline Colomba +17
    Clinical Genitourinary CancerPeer-reviewedLicence not stated19 citedGeneral biologyHAL
  4. Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort
    Silvia Gallo, Carlo Alberto Artusi, Claudia Ledda +11
    Movement Disorders Clinical PracticePeer-reviewedLicence not statedFull textNeurosciencePMC
  5. Pharmacokinetics and efficacy of tank-water-administered dabrafenib, a BRAF inhibitor, in a zebrafish model of melanoma
    Jenna Villman, Nikol Dibus, Jonas Huhn +6
    Disease Models & MechanismsPeer-reviewedCC BY 4.0Full text1 citedCell biologyPMC

Cite

BibTeXRIS
BibTeX
@article{chen2026updated,
  title = {{563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion}},
  author = {Jing Chen and Fei Wang and Shanshan Wang and Xuyang Song and Chia-Chi Lin and Xiaodong Tang and Xuyang Lu and Yutao Liu and Herbert H Loong and Liu Jiayong and Niu Xiaohui and Chung Cheung Thomas Yau and Archie Tse},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0563},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0563},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion
AU  - Jing Chen
AU  - Fei Wang
AU  - Shanshan Wang
AU  - Xuyang Song
AU  - Chia-Chi Lin
AU  - Xiaodong Tang
AU  - Xuyang Lu
AU  - Yutao Liu
AU  - Herbert H Loong
AU  - Liu Jiayong
AU  - Niu Xiaohui
AU  - Chung Cheung Thomas Yau
AU  - Archie Tse
PY  - 2026
DA  - 2026/11/04
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0563
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0563
SN  - 2051-1426
ER  -